Eletriptan Hydrobromide
FDA-approved product (tablet, oral), marketed as Eletriptan Hydrobromide, Relpax.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Migraine disorder
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Selective serotonin (5ht1) agonists
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA45.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae24.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Eletriptan Hydrobromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- RegorafenibExisting use: Cancer, Colorectal adenocarcinoma, Colorectal cancer and 3 more59.6% AI-predicted activityagainst MRSA50+ registered studies
- Omacetaxine MepesuccinateExisting use: Cancer, Neoplasm59.3% AI-predicted activityagainst MRSA50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more59.3% AI-predicted activityagainst MRSA26 registered studies
- Levocabastine HydrochlorideExisting use: Eye allergy, Nasal congestion59.2% AI-predicted activityagainst MRSA5 registered studies
- Zavegepant HydrochlorideExisting use: Migraine disorder59.2% AI-predicted activityagainst MRSANo documented evidence found
- Rocuronium BromideExisting use: Other quaternary ammonium compounds59.1% AI-predicted activityagainst MRSA50+ registered studies
- Ribociclib SuccinateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more59.1% AI-predicted activityagainst MRSA1 registered study
- FulvestrantExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst MRSA50+ registered studies
- PemigatinibExisting use: Cancer, Cholangiocarcinoma, Neoplasm59.0% AI-predicted activityagainst MRSA50+ registered studies
- DutasterideExisting use: Benign prostatic hyperplasia, Prostate adenocarcinoma, Prostate carcinoma59.0% AI-predicted activityagainst MRSA50+ registered studies
- Vincristine SulfateExisting use: Neoplasm59.0% AI-predicted activityagainst MRSA50+ registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease58.9% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury
NCT06677229 · start 2025-08-01
Registered record
- Registry ID
- NCT06677229
- Conditions
- Acute Spinal Cord Injury (SCI)
- Interventions
- Eletriptan HBr 40 mg
- Study type
- INTERVENTIONAL
- Phase
- Phase 1 / Phase 2
- Registry status
- Recruiting
- Start
- 2025-08-01
- Completion
- 2027-06
- Enrolment
- 28
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Spinal Cord Injury (SCI)InterventionEletriptan HBr 40 mgPhasePhase 1 / Phase 2Registry statusRecruitingEletriptan Pharmacokinetics In Korean Males
NCT01139515 · start 2010-07
Registered record
- Registry ID
- NCT01139515
- Conditions
- Healthy
- Interventions
- Eletriptan commercial tablet; Eletriptan commercial tablet; Eletriptan commercial tablet; Eletriptan commercial tablet
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2010-07
- Completion
- 2010-07
- Enrolment
- 16
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionEletriptan commercial tablet; Eletriptan commercial tablet; Eletriptan commercial tablet; Eletriptan commercial tabletPhasePhase 1Registry statusCompleted